Risk factors for invasive aspergillosis in living donor liver transplant recipients

Liver Transplantation

Volumn 13, Issue 4, 2007, Pages 566-570

  Osawa, Makoto ^a   Ito, Yutaka ^a   Hirai, Toyohiro ^a   Isozumi, Rie ^a   Takakura, Shunji ^a   Fujimoto, Yasuhiro ^b   Iinuma, Yoshitsugu ^a   Ichiyama, Satoshi ^a   Tanaka, Koichi ^c   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; FLOMOXEF; FLUCONAZOLE; FLUCYTOSINE; GANCICLOVIR; INSULIN; ITRACONAZOLE; KANAMYCIN; METHYLPREDNISOLONE; MICONAZOLE; TACROLIMUS;

ADULT; ARTICLE; ASPERGILLOSIS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; FEMALE; GRAFT RECIPIENT; HEPATITIS; HUMAN; INCIDENCE; INFECTION RISK; INTENSIVE CARE UNIT; JAPAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MALE; PNEUMOCYSTOSIS; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURGICAL RISK; SURVIVAL TIME; UNIVARIATE ANALYSIS;

ADULT; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ASPERGILLOSIS; BACTERIAL INFECTIONS; CEPHALOSPORINS; FEMALE; HUMANS; IMMUNOSUPPRESSION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34247244732     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21099     Document Type: Article

References (21)

1. Neuhaus P. Live donor/split liver grafts for adult recipients: when should we use them? Liver Transpl 2005; 11: S6-S9.
2. Kiuchi T, Kasahara M, Uryuhara K, Inomata Y, Uemoto S, Asonuma K, et al. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999;67:321-327.
3. Takada Y, Haga H, Ito T, Nabeshima M, Ogawa K, Kasahara M, et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006;81:350-354.
4. Iinuma. Y, Senda K, Fujihara N, Saito T, Takakura S, Kudo T, et al. Surgical site infection in hving-donor liver transplant recipients: a prospective study. Transplantation 2004;78:704-709.
5. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18:44-69.
6. Singh N, Arnow PM, Bonham A, Dominguez E, Paterson DL, Pankey GA, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997;64: 716-720.
7. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999,78:123-138.
8. Fortún J, Martin-Dávila P, Moreno S, de Vicente E, Nuño J, Candelas A, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002;8:1065-1070.
9. Patel R, Portela D, Badley AD, Harmsen WS, Larson-Keller JJ, Ilstrup DM, et al. Risks factors of invasive candida and non-candida fungal infections after liver transplantation. Transplantation 1996;62:926-934.
10. Kusne S, Torre-Cisneros J, Manez R, Irish W, Martin M, Fung J, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992; 166: 1379-1383.
11. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
12. Singh N, Avery RK, Munoz P, Pruett TL, Alexander B, Jacobs R, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003;36:46-52.
13. Selby R, Ramirez CB, Singh R, Kleopoulos I, Kusne S, Starzl TE, et al. Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression. Arch Surg 1997; 132:304-310.
14. Gavalda J, Len O, San Juan R, Aguado JM, Fortun J, Lumbreras C, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005,41:52-59.
15. Fujiwara K, Yokosuka O, Kojima H, Kanda T, Saisho H, Hirasawa H, et al. Importance of adequate immunosuppressive therapy for the recovery of patients with "life-threatening" severe exacerbation of chronic hepatitis B. World J Gastroenterol 2005; 11: 1109-1114.
16. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 729-737.
17. Hellinger WC, Bonatti H, Yao JD, Alvarez S, Brumble LM, Keating MR, et aL Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 2005; 11: 656-662.
18. Linden PK, Coley K, Fontes P, Fung JJ, Kusne S. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin Infect Dis 2003;37:17-25.
19. Hauggaard A, Ellis M, Ekelund L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol 2002;43: 292-298.
20. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417-1427.
21. Stynen D, Goris A, Sarfati J, Latgé JP. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995,33:497-500.